Forum Financial Management LP Makes New Investment in Qiagen (NYSE:QGEN)

Forum Financial Management LP bought a new stake in Qiagen (NYSE:QGEN) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 4,971 shares of the company’s stock, valued at approximately $221,000.

Several other large investors have also made changes to their positions in QGEN. Brown Brothers Harriman & Co. bought a new position in Qiagen during the 4th quarter valued at about $37,000. Geneos Wealth Management Inc. increased its holdings in shares of Qiagen by 41.5% during the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock worth $38,000 after buying an additional 251 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Qiagen by 152.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company’s stock valued at $39,000 after acquiring an additional 526 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Qiagen in the 3rd quarter worth approximately $53,000. Finally, Smartleaf Asset Management LLC grew its position in Qiagen by 148.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company’s stock worth $63,000 after acquiring an additional 835 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

QGEN opened at $42.33 on Wednesday. The company has a fifty day moving average price of $39.80 and a two-hundred day moving average price of $41.71. The firm has a market capitalization of $9.41 billion, a PE ratio of 117.87, a P/E/G ratio of 2.39 and a beta of 0.62. Qiagen has a 52 week low of $37.63 and a 52 week high of $49.30. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. As a group, analysts anticipate that Qiagen will post 2.26 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Morgan Stanley reiterated an “equal weight” rating and issued a $46.67 price objective (down previously from $48.61) on shares of Qiagen in a research report on Monday, January 6th. UBS Group reduced their price target on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Baird R W cut shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Robert W. Baird upped their target price on shares of Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a research report on Monday. Finally, Redburn Atlantic cut shares of Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday, April 4th. Eight research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $47.83.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.